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131Comparison of covered stents versus bare metal
stents for treatment of chronic atherosclerotic
mesenteric arterial disease
Gustavo S. Oderich, MD,a Luke S. Erdoes, MD,b Christopher LeSar, MD,c Bernardo C. Mendes, MD,a
Peter Gloviczki, MD,a Stephen Cha, MS,a Audra A. Duncan, MD,a and Thomas C. Bower, MD,a Rochester,
Minn; Bethesda, Md; and Chattanooga, Tenn
Objective: To compare outcomes of mesenteric angioplasty and stenting using iCAST covered stents (CS; Atrium,
Hudson, NH) or bare metal stents (BMS) in patients with chronic mesenteric ischemia (CMI).
Methods:We reviewed the clinical data of 225 patients (65 male and 160 female; mean age, 726 12 years) treated for CMI
at two academic centers (2000-2010). Outcomes were analyzed in patients who had primary intervention or reinter-
vention using BMS (n [ 164 patients/197 vessels) or CS (n [ 61 patients/67 vessels). End points were freedom from
restenosis, symptom recurrence, reinterventions, and patency rates.
Results: Patients in both groups had similar demographics, cardiovascular risk factors, and extent of disease. In the
primary intervention group (mean follow-up, 29 6 12 months), patients treated by CS had higher freedom from
restenosis (92% 6 6% vs 53% 6 4%; P [ .003), symptom recurrence (92 6 4% vs 50 6 5%; P [ .003), reintervention
(91% 6 6% vs 56% 6 5%; P [ .005), and better primary patency at 3 years (92% 6 6% vs 52% 6 5%; P < .003) than for
BMS. In the reintervention group (mean follow-up, 24 6 9 months), patients treated by CS had higher freedom from
restenosis (89% 6 10% vs 49% 6 14%; P < .04), symptom recurrence (100% vs 64%6 9%; P [ .001), and reintervention
(100% vs 72% 6 9%; P[ .03) at 1 year, and a trend toward improved primary patency at 1 year (100% vs 63% 6 9%; P[
.054). Secondary patency rates were similar in both groups.
Conclusions: In this nonrandomized study, CS were associated with less restenosis, recurrences, and reinterventions than
BMS in patients undergoing primary interventions or reinterventions for CMI. (J Vasc Surg 2013;58:1316-24.)Endovascular revascularization has surpassed open
bypass as the most frequently utilized treatment for chronic
mesenteric ischemia (CMI).1 Several centers have adopted
an endovascular-ﬁrst approach, relegating open surgical
revascularization to patients who fail stenting or have an
anatomy unsuitable for it. It has been generally accepted
that percutaneous angioplasty and stenting of high-grade
superior mesenteric artery (SMA) stenosis or occlusion
provide excellent symptom relief in patients with classic
symptoms of mesenteric ischemia.2-5 Although there is
controversy surrounding the ideal type of stent (balloon
vs self-expandable, covered vs bare metal, 0.035 vs
0.014- to 18-inch platform) and the best approach
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6done using bare metal balloon-expandable stents to treat
ostial lesions or self-expandable stents for distal lesions
affecting tortuous segments.
Despite the widespread acceptance of angioplasty and
stenting and short-term advantages over open bypass,
mesenteric stents are plagued by high rates of restenosis
and reinterventions affecting as much as 20% to 66% of
patients treated for CMI.2-5 Covered stents (CS) have
been associated with decreased rates of restenosis when
applied to treat failing arteriovenous ﬁstulas,6 iliac occlusive
disease,7 and for realignment of renal arteries during fenes-
trated endovascular repair of aortic aneurysms.8 In the
mesenteric arteries, Schoch and associates reported no
restenosis or reinterventions after a mean follow-up of 7
months in 14 patients treated by CS.9 A possible explana-
tion for the low restenosis rate may be that CS act as a phys-
ical barrier to retard development of intimal hyperplasia, in
contrast to bare metal stents (BMS). The purpose of this
study was to compare outcomes in patients treated for
CMI with mesenteric stenting using bare metal or iCAST
CS (Atrium, Hudson, NH) in two academic centers.
METHODS
The study was approved by the Institutional Review
Board of the Mayo Clinic and University of Tennessee,
Chattanooga. The clinical data of consecutive patients
treated for CMI between 2000 and 2010 in the two
participating institutions were retrospectively reviewed
using a standardized database. We included patients treated
Table I. Clinical characteristics of patients treated for CMI by percutaneous transluminal angioplasty and stenting using
BMS or CS
Primary intervention group
P value
Reintervention group
P value
All patients,
BMS
(n ¼ 147)
CS
(n ¼ 42)
BMS
(n ¼ 15)
CS
(n ¼ 21)
No. (%) No. (%) No. (%)
Demographics
Age, years, mean 6 SD 72 6 12 73 6 12 73 6 10 .91 69 6 17 67 6 9 .67
Female 160 (71) 98 (67) 31 (74) .48 12 (80) 19 (90) .37
Clinical presentation
Abdominal pain 210 (93) 139 (95) 38 (90) .3 15 (100) 18 (86) .13
Weight loss 177 (79) 119 (81) 31 (74) .46 12 (80) 15 (71) .56
Food fear 95 (42) 74 (50) 10 (24) .002 5 (33) 6 (29) .76
Cardiovascular risk factors
Hypertension 195 (87) 127 (86) 36 (86) .82 14 (93) 18 (86) .47
Cigarette smoking 134 (60) 87 (59) 22 (52) .23 10 (67) 15 (71) .25
Hyperlipidemia 139 (62) 94 (64) 26 (62) .9 10 (67) 9 (43) .16
CAD 141 (63) 93 (63) 28 (67) .84 11 (73) 9 (43) .07
COPD 60 (27) 44 (30) 6 (14) .026 4 (27) 6 (29) .9
CKD stage IV and V 49 (22) 35 (24) 7 (17) .4 5 (33) 2 (10) .08
Diabetes 56 (25) 36 (24) 12 (29) .7 3 (20) 5 (24) .79
CHF 29 (13) 24 (16) 3 (8) .32 2 (13) 0 (0) .09
BMS, Bare metal stents; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; CMI, chronic mesenteric ischemia; COPD,
chronic obstructive pulmonary disease; CS, covered stents; SD, standard deviation.
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iCAST CS. CMI was diagnosed in patients with one or
more symptoms (abdominal pain, postprandial pain,
weight loss, “food fear”) for >2 weeks and angiographic
evidence of high-grade stenosis or occlusion of the celiac
axis or SMA. Patients treated for acute mesenteric
ischemia, asymptomatic lesions, vasculitis, median arcuate
ligament syndrome, and those treated by open surgical
bypass, fenestrated endografts, angioplasty alone, or endo-
vascular interventions performed in failing bypass grafts,
were excluded from the study.
Demographics, clinical characteristics, and radiologic
and procedural data were obtained from the medical
records. Operative risk was assessed using Society for
Vascular Surgery comorbidity scores.10 Early postproce-
dure events were deﬁned as occurring within the ﬁrst 30
days or within hospital stay if longer than 30 days. Late
follow-up was obtained from review of medical records,
correspondence with patient or referral physician, phone
interview, or questionnaire.
Technical success was deﬁned by <30% residual
stenosis on completion angiography. Follow-up consisted
of clinical examination and duplex ultrasound (DUS) every
6 months during the ﬁrst year and annually thereafter. A
DUS was obtained immediately after the procedure or
within the ﬁrst month after the intervention to determine
baseline velocity measurements whenever possible. Reste-
nosis was deﬁned by DUS peak systolic velocity (PSV)
>330 cm/s or >50% luminal reduction by conventional
mesenteric angiography.11-13 In select patients with
symptom recurrence or restenosis found by DUS,
a computed tomography angiography was obtained toplan reintervention or further evaluate the extent of reste-
nosis/occlusion. Conventional mesenteric angiography
was used for this purpose or when reintervention was
considered. Medical treatment included antiplatelet
therapy (acetylsalicylic acid and/or clopidogrel), which
was continued after the procedure at the discretion of the
treating physician. In general, acetylsalicylic acid was
started prior to the procedure, and clopidogrel was added
for the ﬁrst 4-8 weeks after the intervention.
Type of revascularization. The choice of method of
revascularization was similar in both institutions. Endovas-
cular treatment with primary stenting was used whenever
possible since 2002, relegating open repair to patients who
failed endovascular approach, or those with long occlusions
or large eccentric calciﬁcations.14,15 The choice of stent was
left at the discretion of the treating physician. CS were
increasingly utilized since 2006 and were the preferred stent
after reports of decreased restenosis by Schoch et al.9
Reinterventions were indicated for recurrent symptoms or
in asymptomatic patients with worsening restenosis, very
elevated velocities, and tardus pardus waveform suggestive
of a preocclusive lesion.
Statistical analysis. Data were analyzed using deﬁni-
tions proposed by the Society for Vascular Surgery re-
porting standards for lower extremity interventions.16
Outcomes were analyzed in two groups separately. The
primary intervention group comprised patients who had
their ﬁrst index intervention by stent placement of a native,
untreated celiac axis, or SMA. The reintervention group
consisted of patients who had their ﬁrst reintervention by
stent placement after prior treatment by angioplasty alone
or stent. Patients treated by angioplasty or stenting for
Table II. Anatomic and procedural characteristics of patients treated for CMI by percutaneous transluminal angioplasty
and stenting using BMS or CS
Primary intervention group
P value
Reintervention group
P value
All patients,
No. (%)
BMS
(n ¼ 147)
CS
(n ¼ 42)
BMS
(n ¼ 15)
CS
(n ¼ 21)
No. (%) No. (%)
Approach
Femoral 156 (69) 100 (68) 28 (67) 1 13 (87) 15 (71) .42
Brachial 69 (31) 47 (32) 14 (33) 1 2 (13) 6 (29) .42
Vessel stented
Celiac 82 (36) 57 (39) 12 (29) .27 5 (33) 7 (33) 1
SMA 174 (77) 119 (81) 29 (69) .13 11 (73) 14 (66) .72
IMA 7 (3) 5 (3) 1 (2) 1 0 1 (5) 1
Single-vessel stent 187 (83) 116 (79) 37 (88) .26 14 (93) 20 (95) 1
Stent length, mm 19 6 6 19 6 7 19 6 5 .82 16 6 3 19 6 3 .07
Celiac 17 6 4 17 6 4 17 6 3 .97 16 6 3 19 6 3 .11
SMA 19 6 7 20 6 7 20 6 6 .88 16 6 3 18 6 3 .04
IMA 15 6 1 14 6 1 16 6 0 0 16 6 0
Stent diameter, mm 6.2 6 0.8 6.3 6 0.9 6.2 6 0.5 .39 5.9 6 0.7 6.0 6 0.6 .60
BMS, Bare metal stents; CMI, chronic mesenteric ischemia; CS, covered stents; IMA, inferior mesenteric artery; SMA, superior mesenteric artery.
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were symptom improvement, patency rates and freedom
from restenosis (PSV >330 cm/s), symptom recurrence,
and reintervention. Time-dependent outcomes were
analyzed using Kaplan-Meier methods, and differences
were determined by log-rank test. Univariate and multi-
variate analysis were used to identify clinical, anatomic, and
procedural factors associated with restenosis, symptom
recurrence, reintervention, and loss of primary vessel
patency. Results were reported as percent or odds ratio
with 95% conﬁdence interval (CI). The Pearson c2 or
Fisher exact test was used for analysis of categorical vari-
ables. Differences between means were tested with
two-sided t-test, the Wilcoxon rank-sum test, or the Mann-
Whitney test. A value of P < .05 was used to determine
statistical signiﬁcance.
RESULTS
Patient characteristics. There were 352 patients
treated for CMI during the study period. From this group,
105 patients (30%) were treated by surgical bypass, and
247 (70%) had endovascular revascularization using stents
in 225 (64%) or primary angioplasty in 22 (6%). Two
hundred twenty-ﬁve patients, 160 females and 65 males
with a mean age of 72 6 12 years old (range, 21-90) were
included in the study, and divided into two treatment
groups for analysis (Table I). The primary intervention
group comprised 189 patients treated by BMS in 147
(78%) and CS in 42 (22%). The reintervention group
consisted of 36 patients treated by BMS in 15 or CS in 21.
Demographics, clinical presentation, and cardiovascular
risk factors were similar in both groups, with the exception
of more chronic obstructive pulmonary disease in the
primary BMS group (30% vs 14%; P < .03) and a trend
toward more coronary artery disease (73% vs 43%; P < .07)and stage IV or V chronic kidney disease in the reinter-
vention BMS group (Table I).
Extent of disease and procedural characteristics.
There was no difference in the extent of mesenteric disease,
which affected multiple vessels in 218 patients (96%),
including 183 (97%) in the primary intervention and 35
(97%) in the reintervention groups. There were no signiﬁ-
cant differences in the type of approach, number of vessels
treated, and stent dimensions used for patients treated by
BMS or CS in the primary or reintervention groups
(Table II). The procedure was performed using a trans-
femoral approach in 156 patients (69%) and a transbrachial
approach in 69 (31%). In the primary intervention group,
single-vessel stenting was used in 153 patients (81%), SMA
stenting in 148 (78%), and celiac axis stenting in 69 (36%).
In the reintervention group, the target vessel was the SMA
in 25 patients (69%) and celiac axis in 12 (33%).
Primary intervention group. There were 147
patients/181 vessels treated by BMS and 42 patients/42
vessels treated by CS in the primary intervention group.
Type of lesion was stenosis in 180 vessels (81%; 145
BMS and 35 CS) and occlusion in 43 (19%; 36 BMS and
seven CS; P ¼ .9). Technical success was achieved in 141
patients (95%) treated by BMS and 41 (98%) who had
CS (P ¼ .74). All ﬁve technical failures were from persistent
stenosis >30% because of excessive calciﬁcation. One
patient in each group had intraprocedural dissection, which
was successfully treated by placement of an additional stent,
with no residual lesion. Early symptom improvement was
noted in 140 patients (94%) treated by BMS and in 41
(98%) who had CS (P ¼ .9). There were four (3%) early
procedure-related deaths in the BMS group, two from
mesenteric ischemia caused by distal embolization and
one each from massive gastrointestinal hemorrhage or
myocardial infarction. There were no early deaths among
Table III. Early mortality and morbidity of patients treated for CMI by percutaneous transluminal angioplasty and
stenting using BMS or CS
Primary intervention group
P value
Reintervention group
P value
All patients,
No. (%)
BMS
(n ¼ 147)
CS
(n ¼ 42)
BMS
(n ¼ 15)
CS
(n ¼ 21)
No. (%) No. (%)
Mortality 4 (2) 4 (3) 0 .57 0 0
Morbidity 39 (17) 31 (21) 5 (12) .26 1 (7) 2 (10) 1
Cardiac complications 3 (1.3) 2 (1) 0 1 0 1 (5) 1
Pulmonary complications 2 (0.9) 2 (1) 0 1 0 0
Renal insufﬁciencya 5 (2) 5 (3) 0 .35 0 0
Neurologic complications 2 (0.9) 2 (1) 0 1 0 0
Transient ischemic attack 1 (0.4) 1 (0.7) 0 1 0 0
Median nerve palsy 1 (0.4) 1 (0.7) 0 1 0 0
Gastrointestinal complications 10 (4) 9 (6) 1 (2) .46 0 0
Acute bowel ischemia 5 (2.2) 5 (3) 0 .35 0 0
Gastrointestinal bleeding 3 (1.3) 3 (2) 0 .59 0 0
Segmental bowel resection 2 (0.9) 2 (1) 0 1 0 0
Prolonged ileus 1 (0.4) 0 1 (2) .22 0 0
Access site complications 16 (7) 10 (7) 4 (10) .73 1 (7) 1 (5) 1
Pseudoaneurysm/hematoma 13 (6) 7 (5) 4 (9) .26 1 (7) 1 (5) 1
Thrombosis 1 (0.4) 1 (0.7) 0 1 0 0
AV ﬁstula 2 (0.9) 2 (1) 0 1 0 0
Other
Stent thrombosis 1 (0.4) 1 (0.7) 0 1 0 0
AV, Arteriovenous; BMS, bare metal stents; CMI, chronic mesenteric ischemia; CS, covered stents.
aRenal insufﬁciency did not require dialysis and was deﬁned by >50% increase in baseline creatine and/or serum creatinine >1.5 mg/dL.
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patients (21%) treated by BMS and in ﬁve (12%) who had
CS (P ¼ .26; Table III). Length of stay was similar in both
groups, averaging 1.5 6 2.1 vs 1.3 6 2.4 days, respectively
(P ¼ .88).
The mean follow-up was 29 months (range, 3-132
months) and was signiﬁcantly longer for patients treated
by BMS (32 6 20 months) compared with those who
had CS (19 6 12 months; P < .05). Restenosis occurred
in 62 patients (42%) treated by BMS and in ﬁve (12%)
who had CS, using the PSV ultrasound criteria of >330
cm/s (P < .0002). Of these 67 patients, 48 of them
(32%) treated by BMS and four (10%) who had CS devel-
oped recurrent symptoms (P < .002). Fifty of the 62
patients in the BMS group required 58 reinterventions,
including another stent in 39, angioplasty only in 14,
and open surgical bypass in ﬁve. Four patients (10%) in
the CS group needed six reinterventions, another stent
in three, and angioplasty alone in three. Redo stenting
was done with BMS in 23 patients and CS in 18. Reinter-
vention rate was 24% (36/148) for SMA stents (34/119
BMS and 2/29 CS; P ¼ .009) and 21% (15/70) for celiac
stents (13/56 BMS and 2/14 CS; P ¼ .37). At 3 years,
patients treated by CS had signiﬁcantly higher freedom
from restenosis (92% 6 6% vs 53% 6 4%; P ¼ .003),
symptom recurrence (92% 6 4% vs 50% 6 5%; P ¼
.003; Fig 1), and reintervention (91% 6 6% vs 56% 6
5%; P ¼ .005; Fig 2) than patients treated by BMS.
Primary patency was 92% 6 6% for CS and 52% 6 5%
for BMS at 3 years (Fig 3, A; P < .003). Secondarypatency was 100% for CS and 92% 6 3% for BMS at 3
years (Fig 3, B; P ¼ .45).
Multivariate analysis for predictors of loss of primary
patency, symptom recurrence and reintervention was per-
formed in the primary intervention group. Factors identiﬁed
by univariate analysis were used in a regression model,
including stent type, age, sex, smoking history, lesion
length, and vessel diameter. Of these, multivariate analysis
showed that use of CS was considered a protective factor,
with higher primary patency (hazard ratio [HR], 0.13;
95% CI, 0.032-0.58; P ¼ .0073), less symptom recurrence
(HR, 0.14; 95% CI, 0.034-0.57; P ¼ .0063), and reinter-
ventions (HR, 0.14; 95% CI, 0.035-0.60; P ¼ .008). Other
independent predictors of loss of primary patency were age
(HR, 0.98; 95% CI, 0.96-0.99; P ¼ .0074) and female sex
(HR, 2.2; 95% CI, 1.09-4.57; P ¼ .028). Female sex was
independently associated with recurrent symptoms (HR,
2.49; 95% CI, 1.24-4.97; P ¼ .0096) and reinterventions
(HR, 3.2; 95% CI, 1.5-6.8; P ¼ .0022). Current smoking
history also was associated with symptom recurrence (HR,
3.11; 95% CI, 1.53-6.29; P ¼ .0016).
Reintervention group. There were 15 patients/16
vessels treated by BMS and 21 patients/22 vessels treated
by CS in the reintervention group. The initial index inter-
vention was angioplasty alone in ﬁve vessels (two BMX and
three CS) or primary stenting with a BMS in 32 (14 BMS
and 18 CS; P ¼ .9). Technical success was achieved in 12
patients (80%) treated by BMS and 21 (100%) who had CS
(P ¼ .03). The three patients treated by BMS had residual
narrowing >30%. There were no procedure-related deaths.
Fig 1. Kaplan-Meier estimates of freedom from symptom recur-
rence in patients treated by primary interventions for chronic
mesenteric ischemia (CMI) using bare metal stents (BMS) or
covered stents (CS).
Fig 2. Kaplan-Meier estimates of freedom from reintervention in
patients treated by primary interventions for chronic mesenteric
ischemia (CMI) using bare metal stents (BMS) or covered stents
(CS).
Fig 3. Kaplan-Meier estimates of primary (A) and secondary
patency rates (B) in patients treated by primary interventions for
chronic mesenteric ischemia (CMI) using bare metal stents (BMS)
or covered stents (CS).
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one (6.6%) patient treated by BMS and two (9.5%) who
had CS. Symptom improvement was noted in 14 patients
(93%) treated by BMS and in all 21 patients who had CS
(P ¼ .41).
The mean follow-up was 24 months (range, 3-83
months) in this group and was longer for patients treated
by BMS (38 6 25 months) than in those who had CS
(21 6 14 months; P < .01). Nine patients (60%) treated
by BMS and four (19%) who had CS developed another
restenosis after redo stenting (P ¼ .01). Recurrent symp-
toms occurred in nine patients treated by BMS, correlated
to recurrent stenosis, and were treated with redo stenting
in seven and open surgical bypass in two. Three patients
who had CS required additional redo stent placement for
recurrent symptoms. The reintervention rate was 32% (8/
25) for SMA stents (6/11 BMS and 2/14 CS; P ¼ .04)
and 33% (4/12) for celiac stents (3/5 BMS and 1/7 CS;
P ¼ .15). At 1 year, patients treated by CS had signiﬁcantly
higher freedom from restenosis (89% 6 10% vs 49% 6 14%;
P < .04), symptom recurrence (100% vs 64 6 9%;P ¼ .001), and reintervention (100% vs 72 6 9%;
P ¼ .03) than those who had reinterventions by BMS.
Primary patency at 1 year was 100% for CS and 63% 6
9% for BMS (Fig 4, A; P ¼ .054). Secondary patency at 1
year was 100% in both groups (Fig 4, B; P ¼ .09).
DISCUSSION
During the last decade, there has been a threefold
increase in the number of mesenteric revascularizations per-
formed in the U. S., largely because of the increasing
number of patients treated by mesenteric stents for acute
and CMI.1 Unfortunately, mesenteric stenting has been
fraught with high rates of restenosis and reinterventions,
not matching the excellent patency rates reported for open
surgical reconstructions.2-5 This nonrandomized compar-
ison has shown improved outcomes for CS compared with
BMS. CS outperformed BMS, with less restenosis, symptom
recurrences, reinterventions, and better patency rates. These
observations held fast both in primary interventions for
native artery lesions and in reinterventions for in-stent or
native artery restenosis after endovascular procedure. These
data support the high restenosis rates with BMS reported
by others and challenge the current paradigm of choice of
stent for endovascular treatment of CMI.2-5,11-14
Fig 4. Kaplan-Meier estimates of primary (A) and secondary
patency rates (B) in patients treated by reinterventions for chronic
mesenteric ischemia (CMI) using bare metal stents (BMS) or covered
stents (CS). The dotted line represents standard deviation >10%.
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treated by stenting for CMI.2-5,11,17-19 Several factors
account for this high variability. There are currently no
reporting standards or consensus on the deﬁnition of in-
stent restenosis, which largely is based on surveillance DUS
imaging. Moreover, the routine use of postinterventional
imaging studies is inconsistent, the speciﬁc velocity criteria,
which deﬁne high-grade in-stent stenosis are controversial,
and the validity of these criteria remain in question because
there are few papers that compare ultrasonography with
contrast angiography. AbuRahma and associates reported
a retrospective review of paired DUS and contrast angiog-
raphy in 150 patients treated by mesenteric stents. The
PSV that had the best overall accuracy to identify >50%
SMA stenosis was 295 cm/s, whereas a PSV >400 cm/s
indicated stenosis >70%.20 Baker and colleagues noted
that the average PSV measured immediately after placement
of mesenteric stents was 335 cm/s, increasing to 390 cm/s
by the end of the ﬁrst year.21
Our choice of a PSV >330 cm/s to indicate at least
moderate recurrent stenosis is in line with AbuRahma’s
ﬁndings and was based in part on previous data from our
institution by Tallarita and associates.11 In that study,
outcomes of 30 patients treated for in-stent restenosis
were examined.11 The average PSV was 304 cm/s immedi-
ately after successful stent placement, reaching 440 cm/s at
the time of a second intervention. The type and location of
restenosis was also analyzed using contrast angiography.
Intimal hyperplasia within the stented segment accounted
for 43% of the 30 cases of restenosis, while 57% of patients
had restenosis affecting arterial segments proximal or distal
to the stent edge. Importantly, in 43% of the patients, the
area of restenosis coincided with technical imperfections
noted on review of the index completion angiography per-
formed at the time of the ﬁrst intervention. This ﬁnding
emphasizes how critical it is to pay attention to detail at
the time of the ﬁrst mesenteric intervention. Furthermore,
some “restenosis” reported on postintervention ultrasound
imaging may actually represent incomplete or inadequate
treatment, rather than progression of disease or develop-
ment of neointimal hyperplasia. Technical imperfections
include inadequate stent length or treatment segment, or
poor stent expansion because of unfavorable anatomy,
such as with highly calciﬁed or eccentric lesions.
Multiple approaches have been used to treat in-stent re-
stenosis. Innovative techniques to maintain an “endovascular-
ﬁrst approach” have included balloon angioplasty with
cutting or cryoplasty balloons, redo stenting with bare
metal or drug-eluting stents,22 and atherectomy.23 The
latter has been used either as primary therapy or as an
adjunct to debulk areas of neointimal hyperplasia prior to
angioplasty or stenting. To date, none of these approaches
has shown any beneﬁt compared with standard angioplasty
alone.
The interest in CS to treat mesenteric lesions origi-
nated from improved patency rates reported with such
stents in other vascular beds when used for different indi-
cations. Haskal and associates reported a prospective,randomized trial that demonstrated the beneﬁt of using
CS to treat failing arteriovenous grafts.6 Their data showed
a doubling of primary patency rates (51% vs 21%) and
reduced reintervention rates when CS were used to treat
venous outﬂow stenosis, albeit at follow-up limited to six
months.6 The Covered Versus Balloon Expandable Stent
Trial (COBEST) was a prospective, multicenter, random-
ized controlled trial that compared the outcomes of
patients treated with CS vs BMS in the treatment of aor-
toiliac occlusive disease. Lesions treated with CS were
signiﬁcantly more likely to remain free from restenosis
than those treated with BMS (HR, 0.35; 95% CI, 0.15-
0.82; P ¼ .02), and there was a trend toward improved
freedom from occlusion for the CS group.7 The superiority
of CS has also been demonstrated when used for renal
alignment during fenestrated endovascular aortic repair.
Mohabbat et al reviewed the outcomes of 518 renal
arteries treated by alignment stents during fenestrated
endovascular repair.8 Freedom from stenosis at 3 years
was signiﬁcantly higher for CS (95%) than for BMS
(89%). An interesting ﬁnding of the study was the differ-
ence in the location of restenosis observed with the two
types of stents. Whereas restenosis associated with BMS
affected primarily the proximal stented segment and is
JOURNAL OF VASCULAR SURGERY
1322 Oderich et al November 2013noted within the ﬁrst 6 months to 2 years, those with CS
tended to occur distal to the stent edge. A possible expla-
nation for restenosis in the proximal stent may be the over-
dilatation or ﬂare that is required during fenestrated repair,
which may cause intimal and medial injury and a late
hyperplastic response and restenosis. Conversely, graft
coverage of this injured segment may impede ingrowth
of tissue either by acting as a barrier or rendering the arte-
rial wall ischemic.
The clinical data on the use of CS to treat mesenteric
artery disease is scarce. The University of Tennessee group
was the ﬁrst to report favorable results in 14 patients
treated by CS, with no reinterventions after 2-year
follow-up.9 The aforementioned Tallarita study described
no restenosis in four patients treated by mesenteric reinter-
vention with CS, compared with 62% restenosis and 38%
reintervention rates for BMS.11 These lower restenosis
and reintervention rates observed with CS are likely
explained by its barrier to tissue ingrowth. In addition to
serving as a physical barrier, the polytetraﬂuorethylene
covering may also promote local ischemia during balloon
expansion of the stent. Nevertheless, restenosis occurs
from intimal hyperplasia at the stent edges or within the
native artery, or from pseudointima within the stent. It is
possible that with longer follow-up, CS may be affected
by late restenosis from one of these mechanisms.
The patency rates reported for BMS in this study
compare favorably with other contemporary reports.24,25
The average 3-year primary patency rate of 52% (range,
30%-81%) calculated from the pooled literature26 is the
same as ours. The secondary patency of BMS is better
than 90%, as evidenced by reports of mesenteric reinterven-
tions. In this study, CS had excellent primary (92% 6 6%)
and secondary (100%) patency rates at 3 years, rivaling the
results of open surgical bypass.26 However, longer follow-
up is needed to determine rates and mechanisms of late fail-
ures in the CS group. We found higher rates of symptom
recurrence and reinterventions among female patients,
which may reﬂect the smaller vessel diameter in these
patients. Most certainly, case selection is key to achieve
excellent results. Focal, noncalciﬁed lesions in large
(>6 mm) vessels should respond well to endovascular
therapy, but poorer results are expected for long, densely
calciﬁed lesions, and in small arteries (<5 mm).
There are several potential beneﬁts of using a balloon-
expandable CS. These include precise deployment, excel-
lent radial force, prevention of embolism by entrapment
of debris, the ability to overexpand the stent to the desired
diameter with minimal stent foreshortening, and less risk of
arterial disruption because of polytetraﬂuorethylene
coverage. By contrast, the cost of a CS is three to ﬁve times
more than a BMS, and the ﬁrst-generation iCAST stents
(Atrium) did not have the ﬂexibility to handle tight angles
and were prone to dislodge over the balloon. Although the
latter complication did not occur in this series, stent
dislodgement can be associated with disastrous complica-
tions such as coverage of critical branches, which may
lead to open repair. In addition, CS are available ona 0.035-inch platform and most require a 7F sheath,
a major limitation compared with smaller-proﬁle stents
that can be introduced via a 4-6F sheath over a 0.014- to
18-inch guidewire.27 Newer CS designs have addressed
some of these limitations. In 2010, a second-generation
0.035-inch iCAST stent became commercially available
worldwide, replacing the former platform. It has better
ﬂexibility and balloon retention than the older version. A
new 0.018-inch platform has been developed and will be
tested clinically in the near future.
This study has several limitations. First, the choice of
stent was not randomized, and our practice has gradually
evolved from using CS for in-stent restenosis to applying
this stent more widely for native artery lesions. Second,
although stent diameter and length were similar in both
groups, long lesions involving side branches were more
likely to be treated by BMS. Third, the decision making
about stent type, approach, number of vessels treated,
and medical therapy, could not be analyzed because of
the retrospective design and lack of treatment algorithm.
BMS were favored earlier in our experience, whereas CS
were increasingly utilized after the report by Schoch
et al.9 Fourth, we acknowledge that the ultrasound crite-
rion used in this study (PSV >330 cm/s) was arbitrary
and has not been validated for mesenteric in-stent stenosis.
While this velocity may overestimate high-grade restenosis
rates, it is the criterion selected by our group based on
a recent report dealing with the deﬁnition of this problem.
Lastly, follow-up was signiﬁcantly longer in the BMS
group, which may account for differences in time-
dependent outcomes including restenosis, symptom recur-
rence, and reinterventions.
In summary, this nonrandomized study suggests that
CS used to treat mesenteric artery stenosis were associated
with less restenosis, recurrences, and reinterventions in
patients with CMI. These data have changed our practice
paradigm. We currently recommend the use of a CS for
focal stenosis and reserve BMS for patients with long
lesions that involve side branches, or when access issues
limit the use of a 7F system. Longer follow-up and further
validation of the ﬁndings by a prospective randomized
comparison with BMS is needed to prove the superiority
of CS in this position.
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Submitted Jan 16, 2013; accepted May 7, 2013.DISCUSSIONDr Timur Sarac (Cleveland, Ohio). We presented our data at
the Cleveland Clinic approximately 5 years ago and found that our
reintervention rates in this cohort of patients was very high, and
you have taught us now a new way of doing this to really decrease
and cut down on the second procedure. I have two questions for
you.
One is could you please really give us the details of the tech-
nical aspects of using these stents, speciﬁcally in relation to do youﬂare the stent at all? And if so, what level can you take these
atriums to?
And then the second question I have is related to the SMA.
In some patients, we note that there is a long-segment stenosis
or even occlusion, which we have been more aggressive recently
in treating these. And do you use the iCAST in the SMA, or do
you go to a self-expanding stent where you’d go over that long
curve?
JOURNAL OF VASCULAR SURGERY
1324 Oderich et al November 2013Dr Gustavo S. Oderich. I have to say that over the last years,
we really reﬁned our technique, and there are several things that
need to be done to reduce restenosis rate.
I think one of the key points is to size the lesion and to make
sure that you use a stent that is of adequate size. We have learned
from looking at the restenosis that some of the patients were
undertreated and, in fact, either the lesion was missed distally or
proximally at the ostia.
So that brings us to the second point, which is ﬂaring of the
stent. I am really fond of ﬂaring out the stent for two reasons:
one is avoiding missing an ostial lesion and also facilitating recathe-
terization in the event that you need to do a reintervention. And I
tend to ﬂare it using the same balloon most of the time; or if I am
really concerned, upsizing the balloon by 1 or 2 mm.
In terms of some of the technical points of the iCAST, there
are certainly limitations with this. And I would say aside of the
fact that it is approximately three times more expensive, it does
require a larger introducer sheath, which becomes a problem for
those that are fond of using a brachial approach; it is subjected
to dislodgement from the balloon, which has signiﬁcantly
improved with newer technology. There is some risk of covering
side branches such as a large replaced hepatic artery. So, we still
do use uncovered stents on that bend of the SMA. A self-expand-
able stent also becomes a good and attractive option for lesions
beyond the ostia that involve tortuous segments. And, we have
cases that we use the hybrid stent with iCAST proximally for the
ostia and then a self-expandable uncovered stent for the proximal
to midportion of the SMA.
Dr Ali AbuRahma (Charleston, WVa). Gus, I really compli-
ment what you have done over the last several years in this ﬁeld,
and it has been an education to all of us.
The question that I have for you is: What duplex velocity
criteria did you use to validate these in-stent stenoses? And did
you validate these duplex velocities?
Dr Oderich. This is also a very important point and is the
main reason why there is such a variation between rates of resteno-
sis in different reports. The criteria that we use to deﬁne restenosis,
which I think is very debatable, is a peak systolic velocity of approx-
imately 330 cm/s for the SMA. This is based on several recent
reports including yours, Dr AbuRahma. We have not validated
a duplex ultrasound criteria at our institution for in-stent resteno-
sis. The main reason is that we found it difﬁcult to justify doing
angiography on a patient with “high velocities” who is asymptom-
atic and does not need reintervention.
I have to say, though, that there are many patients that despite
the high velocities, still have a widely patent stent. So the curves
that you see for primary patency in our study have included
patients with a restenosis associated with recurrent symptoms or
that require a reintervention, or an occlusion of the stent. Thesewere the criteria that we used; we have not used asymptomatic
restenosis diagnosed by ultrasound. For the purpose of the presen-
tation, I shied away from showing curves of freedom from resteno-
sis, which I think are highly debatable in how you deﬁne that given
that we do not obtain angiography in all patients.
Dr Amy Reed (Hershey, Pa). I just wanted to have you
comment on two things. First, for those BMS that failed, how
many of those did you wind up rescuing with the covered stent,
or did you have to go on to open revascularization?
And also could you comment, just a technical detail about the
management of antiplatelet therapy, if it was long term, if it was
different for the covered vs the uncovered?
Dr Oderich. I think if you have used a balloon-expandable
stent for the ﬁrst intervention, you have the luxury of being able
to size the second stent to the same size of the original stent. So
the answer is yes, for failed BMS, we offer a reintervention ideally
with a covered stent. Repeated restenosis is a different issue, and
the approach somewhat varies in our group, but my general
approach is still to offer to that patient that has a recurrence another
endovascular attempt. And I think the patients that we can predict
that are going to have repeated attempts are the long lesions in
the small vessels, female patients with dense calciﬁcations. And
most certainly in those patients, particularly if they are deemed
good surgical candidates, a bypass I think is a very good alternative.
Importantly, provided that you are careful and you do not compro-
mise the mid to distal portion of the SMAwith your initial endovas-
cular procedure, I do not think you burn any bridges. As for medical
therapy with CS, we recommend clopidogrel for the ﬁrst 6-8 weeks
followed by aspirin, which is the same as with a BMS. This is based
on the fenestrated endografts literature where clopidogrel is usually
not needed as a long-term therapy.
Dr Hasan Dosluoglu (Buffalo, NY). Great paper, and it
supports my bias, so thank you very much for that. I thought
you were going to say that you now routinely perform intravascular
ultrasound (IVUS), as you stated that you usually found the stents
to be undersized. So do you actually use IVUS during these proce-
dures, or do you not?
Dr Oderich. No. So I do not do IVUS for these cases, but I
do use CTA as our main preoperative workup test, and I tend to
size the length and the diameter using centerline or actual dimen-
sions to select the stent.
Dr John Ricotta (Washington, D.C.). This is a sequential
series, so presumably, the covered stents were done later in the
course of the series. Did you look at your BMS patency over
time to see whether it was an issue of technique getting better
that affected some of this?
Dr Oderich. The short answer is I have not, but I think this is
a very good methodological point that we should do for the
manuscript.
